Xencor Gives Panel Presentation and Company Update at BIO InvestorForum; Announces Recent Close of $20 Million in Financing MONROVIA, CA – October 18, 2005 – Xencor, Inc., a biotherapeutics company developing protein therapeutics and antibody drugs, announced today that Bassil Dahiyat, Ph.D.,
Xencor, Inc. Signs Collaboration with Centocor, Inc. to Improve Antibodies Xencor, Inc. licenses engineered Fc domains to Centocor, Inc. to enhance therapeutic efficacy Monrovia, CA – July 18, 2005 – Xencor, Inc., a biotherapeutics company developing protein therapeutics and antibody drugs, today
FierceBiotech Honors Xencor as One of the MONROVIA, CA – June 21, 2005 – Xencor, Inc., a company engineering superior biotherapeutics using its Protein Design Automation® technology, announced today that it has been selected as one of the “Fierce 15“ for 2005 by FierceBiotech, an internationally
Xencor Licenses Protein Variants to Lilly Monrovia, CA – April 13, 2005 – Xencor today announced that Eli Lilly and Company has exercised its option to develop one or more therapeutic proteins created by Xencor under its collaboration with Lilly. Xencor used its proprietary Protein Design
Xencor and Chugai Initiate Partnership for Optimized Antibodies Chugai licenses Xencor’s XmAb™ technology to enhance antibody efficacy Monrovia, CA – January 10, 2005 – Xencor today announced a license and collaboration agreement with Chugai Pharmaceutical Co., Ltd.